Generation and purification of CD8+ Melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1997-2005

  Oelke, Mathias ^a   Moehrle, Ursula ^a   Chen, Ji Li ^b   Behringer, Dirk ^a   Cerundolo, Vincenzo ^b   Lindemann, Albrecht ^a   Mackensen, Andreas ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL TRANSFER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANTIGENS, CD8; ANTIGENS, NEOPLASM; CLONE CELLS; DENDRITIC CELLS; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0034068120     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jäger, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., and Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80: 219-230, 1999.
3. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
4. Rosenberg, S. A., Zhai, Y., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sipp, C. A., Einhorn, J. H., Roberts, B., and White, D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst., 90: 1894-1900, 1998.
5. Melief, C. J. M. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res., 58: 143-175, 1992.
6. Prevost-Blondel, A., Zimermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F. M., and Pircher, H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol., 161: 2187-2194, 1998.
7. Iwasaki, A., Torres, C. A., Ohashi, P. S., Robinson, H. L., and Barber, B. H. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol., 159: 11-14, 1997.
8. Jäger, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., Jäger, D., Ilsemann, C., Hagedorn M., Oesch, F., and Knuth, A. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. In. J. Cancer, 67: 54-62, 1996.
9. Mackensen, A., Herbst, B., Köhler, G., Wolff-Vorbeck, G., Rosenthal, F. M., Veelken, H., Kulmburg, P., Schaefer, H. E., Mertelsmann, R., and Lindemann, A. Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood, 86: 2699-2707, 1995.
10. + hematopoietic progenitor cells toward distinct dendritic cell subsets of the Birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type. Blood, 88: 2541-2548, 1996.
11. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
12. Bakker, A. B. H., Marland, G., de Boer, A. J., Huijbens, R. J. F., Danen, E. H. J., Adema, H. J., and Figdor, C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55: 5330-5334, 1995.
13. Valmori, D., Pittet, M. J., Rimoldi, D., Lienard, D., Dunbar, R., Cerundolo, V., Lejeune, F., Cerottini, J-C., and Romero, P. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res., 59: 2167-2173, 1999.
14. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., and Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol., 162: 2227-2234, 1999.
15. Dunbar, P. R., Chen, J-L., Chao, D., Rust, N., Teisserenc, H., Ogg, G. S., Romero, P., Weynants, P., and Cerundolo, V. Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J. Immunol., 162: 6959-6962, 1999.
16. Manz, R., Assenmacher, M., Pflügler, E., Miltenyi S., and Radbruch, A. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. USA, 92: 1921-1925, 1995.
17. Coulie, P. G., Brichard, V., Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J-P. Renauld, J-C., and Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.
18. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
19. Wölfel, T., Van Pel, A., Brichard, V., Schneider, J., Seeliger, B., Meyer zum Büschenfelde, K-H., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
20. Bednarek, M. A., Sauma, S. Y., Gammon, M. C., Porter, G., Tamhankar, S., Williamson, A. R., and Zweerink, H. The minimum peptide epitope from the influenza virus matrix protein. J. Immunol., 147: 4047-4053, 1991.
21. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
22. Mackensen, A., Wittnebel, S., Veelken, H., Noppen, C., Spagnoli, G. C., and Lindemann, A. Induction and large scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells. Eur. Cytokine Netw., 10: 329-335, 1999.
23. Salter, R. D., Howell, D. N., and Cresswell, P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics, 21: 235-246, 1985.
24. Mackensen, A., Carcelain, G., Viel, S., Raynal, M. C., Michalaki, H., Triebel, F., Bosq, J., and Hercend, T. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Investig., 93: 1397-1401, 1994.
25. Altman, J. D., Moss, P., Goulder, P., Barouch, W. M., McHeyzer, W. M., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Washington DC), 274: 94-96, 1996.
26. Dunbar, P. R., Ogg, G. S., Chen, J., Rust, N., van der Bruggen, P., and Cerundolo, V. Direct isolation, phenotyping and cloning of low frequency antigen-specific CTL from peripheral blood. Curr. Biol., 8: 413-416, 1998.
27. Assenmacher, M., Löhning, M., Scheffold, A., Manz, R. A., Schmitz, J., and Radbruch, A. Sequential production of IL-2, IFN-γ and IL-10 by individual staphylococcal enterotoxin B-activated T helper lymphocytes. Eur. J. Immunol., 28: 1534-1543, 1998.
28. Riddell, S. R., and Greenberg, P. D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods, 128: 189-195, 1990.
29. Levine, B. L., Bernstein, W. B., Connors, M., Craighead, N., Linsten, T., Thompson, C. B., and June, C. H. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol., 159: 5921-5930, 1997.
30. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wie, J. P., and White, D. E. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, special report. N. Engl. J. Med., 319: 1676-1680, 1988.
31. Robbins, P. F., Elgamil, M., Kawakammi, Y., and Rosenberg, S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res., 54: 3124-3126, 1994.
32. Mutis, T., Verdijk, R., Schrama, E., Esendam, B., Brand, A., and Goulmy, E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood, 93: 2336-2341, 1999.
33. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H. The central role of CD4+ T cells in the antitumor immune responses. J. Exp. Med., 188: 2357-2368, 1998.
34. Nelson, B. H., Lord, J. D., and Greenberg, P. D. Cytoplasmic domains of the IL-2 receptor β and γ chains mediate the signal for T cell proliferation. Nature (Lond.), 369: 333-336, 1994.
35. Manici, S., Sturniolo, T., Imro, M. A., Hammer, J., Sinigagkia, F., Noppen, C., Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P., and Protti, M. P. Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med., 189: 871-876, 1999.
36. Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G., Settlage, R. E., Shabanowitz, J., Rosenberg, S. A., Hunt, D. F., and Topalian, S. L. Biochemical identification of a mutated human melanoma antigen recognized by DC4+ T cells J. Exp. Med., 189: 757-765, 1999.
37. Maccalli, C., Farina, C., Sensi, M., Parmiani, G., and Anichini, A. TCRβ-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201 + melanoma patients. J. Immunol., 158: 5902-5913, 1997.